Paul, Weiss client Nichi - Iko Pharmaceutical Co., Ltd., the
largest generic drug manufacturer in Japan by sales, announced that it has agreed to acquire Sagent Pharmaceuticals, Inc. in an all - cash tender offer followed by a second - step cash merger, for a total consideration of approximately $ 736 million.
Early rumors that British pharma giant AstraZeneca's chief executive, Pascal Soriot, was considering jumping ship to the major (and troubled)
generic drug manufacturer Teva sent the biopharma world into a tizzy.
Osler's White, whose firm
represents generic drug manufacturers, says he believes Canada's IP law was already robust before the SCC decision in AstraZeneca, and that given the size of the pharmaceutical industry around the world, «they weren't going to not file for patent applications in Canada.
At issue is whether the Supreme Court should reinforce its 2011 ruling that
protected generic drug manufacturers from state products liability claims accusing them of not warning about possibly dangerous side effects.
Now, the justices are trying to decide
whether generic drug manufacturers can be sued in state court for design defects - especially when the generic version is an exact copy of its brand - name counterpart that the federal government had already approved.
Viventia didn't have such a happy ending, but the company that truly made Dan's fortune was
the generic drug manufacturer Novopharm, which he founded in 1964 and sold to Teva Pharmaceuticals in 2000.
For
a generic drug manufacturer to get the U.S. Food and Drug Administration's (FDA) stamp of approval, they must prove it is pharmaceutically equal to the name - brand version.
* Eliminate «pay - for - delay» strategies in which a pharmaceutical company with a brand name drug shares profits on that drug with
a generic drug manufacturer for the remainder of a patent period, effectively eliminating a patent challenge and competition.
Mediated product - hopping dispute involving antitrust and patent issues between patentee and generic drug manufacturer
Thankur alleges that
the generic drug manufacturer committed Medicare / Medicaid fraud and pharmaceutical fraud.
His family sued
the generic drug manufacturer, which settled for $ 2,600,000.
Patent holders previously made such claims in order to delay the onset of competition from
generic drug manufacturers, by preventing or delaying FDA approval of a generic manufacturer's Abbreviated New Drug Application (ANDA).
There is no cause of action in West Virginia for failure to warn and negligent misrepresentation against a brand - name drug manufacturer when the drug ingested was produced by
a generic drug manufacturer.